Bimetallic redox nanoprobe enhances the therapeutic efficacy of hyperthermia in drug-resistant cancer cells
Cancer nanotheranostics has emerged as one of the most promising fields of medicine wherein nano-sized molecules/agents are used for combined diagnosis and treatment of cancer. Despite promises of novel cancer therapeutic approaches, several crucial challenges have remained to be overcome for successful clinical translation of such agents. Hence, the present study has been aimed to investigate the therapeutic efficacy of bimetallic gadolinium super-paramagnetic iron oxide nanoformulation of ascorbic acid in synergism with hyperthermia on ascorbic acid-resistant breast cancer cells. This particular strategy provides real-time MRI-based non-invasive imaging of drug loading in resistant cancer cells along with highly enhanced therapeutic efficacy. This unique redox nanoprobe is capable of reversing drug-resistance mechanism in cancer cells and offers better therapeutic possibilities in targeted and effective destruction of drug-resistant cancer cells.
KeywordsDrug-resistance cancer Redox nanoprobe Hyperthermia Treatment Bimetallic nanoparticles
The authors thank the Department of Radiology, Princess Esra Hospital, Hyderabad, for providing facility to conduct MRI contrast imaging.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- Athar T, Vishwakarma SK, Bardia A, Khan AA (2016) Super paramagnetic iron oxide and gadolinium (FeGdO3) nanopowder synthesized by hydrolytic approach passes high level of biocompatibility and MRI-based dual contrast property for competent molecular imaging and therapeutic interventions. Biomed Phys Eng Express 2:025010CrossRefGoogle Scholar
- Kuiper C, Vissers MCM (2014) Ascorbate as a co-factor for Fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression. Front Oncol 4:359Google Scholar
- Pollard HB, Levine MA, Eidelman O, Pollard M (2010) Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24:249–256Google Scholar